After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

Nkarta's NKX019 offers hope for autoimmune treatment. Upcoming trial data and strategic moves could fuel recovery. Read more ...

Charles River Laboratories International, Inc. CRL and Valo Health, Inc. recently announced an advanced product candidate for the treatment of different forms of lupus and other autoimmune indications ...

Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators for the treatment of ...

More than one-third of patients with systemic lupus erythematosus experience a flare after starting dialysis for end-stage ...

Medicare covers lupus treatment in different ways depending on your age and how the condition affects you. Read more.

African Americans, particularly women, and residents of Southern states face disproportionately high rates of SLE-related mortality.

A Jordanian study finds that over one-third of women with lupus suffer from depression, and nearly one-third have ...

Nkarta is laying off a third of its employees, including half of the biotech’s executive leadership, as the company diverts ...

Mar. 12, 2025 — Lupus is an autoimmune disease where the body's immune system attacks its own tissues and organs, causing inflammation and damaging organs. A new study has now shown that the ...

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases; Initial data for NKX ...

Three Husker students under the mentorship of Luwen Zhang, a leading University of Nebraska-Lincoln virologist, have achieved ...